Roche Obesity Drug Candidate Improves Both Blood Sugar and Weight in Phase 2 Trial
Roche's obesity treatment candidate, enisefatide, has been shown in Phase 2 trials to significantly lower both blood sugar levels and weight in overweight and obese patients with type 2 diabetes.
On September 22 (local time), Roche announced that, after 48 weeks of treatment, the highest dose group (24 mg) saw a decrease in hemoglobin A1c (HbA1c) by 2.65 percentage points, while body weight was reduced by an average of 15.5%. The company also explained that the weight loss effect had not plateaued even at this time point.
Roche plans to begin a Phase 3 clinical trial and a cardiovascular outcome study in the first half of 2027. Enisefatide is a once-weekly GLP-1/GIP dual agonist. Its former code name was CT-388.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Levi Garraway, Chief Medical Officer (CMO) and Head of Global Product Development at Roche, stated, "Enisefatide has the potential to reduce and prevent complications in patients with type 2 diabetes, as well as improve metabolic health, based on its sustained weight loss effect." He added, "It demonstrates the potential to become a best-in-class therapy in the field of disease treatment."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.